NGS Testing for Biologics Is Becoming a Readiness Issue, Not Just a Science Issue

Biologics manufacturers are facing a familiar challenge in a new form: the science is advancing, but execution will determine whether the technology can be used reliably in regulated operations.

A timely example is FDA’s upcoming scientific public workshop on Next-Generation Sequencing for Adventitious Agent Detection in Biologics, scheduled for September 23, 2026. FDA’s Center for Biologics Evaluation and Research plans to convene regulators, subject matter experts, and stakeholders to discuss the readiness of NGS technologies for adventitious agent detection, implementation challenges, and potential solutions to accelerate adoption of NGS-based methods for biological products. (U.S. Food and Drug Administration)

That matters because adventitious agents are not a small quality concern. FDA notes that contamination from viruses, bacteria, fungi, mycoplasma, and parasites can jeopardize the safety, efficacy, and supply integrity of biological products, including cell and gene therapies, xenotransplantation products, blood products, and vaccines. (U.S. Food and Drug Administration)

For life sciences teams, this is not just a laboratory technology conversation. It is a readiness, validation, documentation, data, quality, and project execution conversation.

NGS Is Moving Closer to Practical Use in Safety Testing

NGS-based adventitious agent detection has been discussed for years because of its ability to broadly detect potential contaminants. FDA describes these methods as new approach methodologies that can enhance biological product safety while reducing reliance on animal testing. (U.S. Food and Drug Administration)

The important shift is that the conversation is becoming more operational.

FDA’s workshop objectives include discussing current advances in NGS technology, implementation challenges, emerging technical requirements, analytical validation, data interpretation, and integration into existing safety testing frameworks. (U.S. Food and Drug Administration)

Those words matter.

“Integration” is where many promising tools struggle. A method can be scientifically powerful and still create practical questions for quality systems, validation plans, data review, SOPs, deviation management, vendor oversight, and regulatory submissions.

In regulated manufacturing, adoption does not happen because a technology is impressive.

It happens when the method can be controlled, justified, documented, reviewed, and sustained.

Why This Matters for Biologics and Advanced Therapies

Biologics, vaccines, blood products, and cell and gene therapies often involve sensitive processes, complex raw materials, living systems, viral vectors, specialized testing, and tight supply timelines.

That means adventitious agent testing is not isolated from the rest of the program. It connects to CMC strategy, materials control, supplier qualification, analytical method readiness, facility operations, contamination control, batch release, and regulatory evidence.

FDA’s Q5A(R2) guidance provides risk-based principles and mitigation strategies to assure viral safety of biotechnology products, including the data needed in marketing applications. The guidance also updates prior expectations based on scientific advances and regulatory experience. (U.S. Food and Drug Administration)

For manufacturers, the takeaway is practical: viral safety and adventitious agent detection need to be built into the execution model early.

If testing strategy, sample flow, data review, bioinformatics, vendor roles, and documentation are not aligned, the issue may not appear until a critical phase of development, validation, submission, or commercial readiness.

That is when a science issue becomes a schedule issue.

The Real Risk Is Poor Implementation

NGS-based testing brings clear promise, but it also brings execution questions.

How will the method be validated?

Who owns the data review?

How will bioinformatics workflows be controlled?

What happens when a signal is detected?

How will results be documented and interpreted?

What vendors or CROs are involved?

How will the method fit into the existing safety testing framework?

How will quality approve, trend, and retain the record?

These are not theoretical questions. They are the questions that determine whether NGS improves readiness or adds another layer of complexity.

A team can have strong scientists and still struggle if ownership is unclear. A company can select a strong testing partner and still lose time if documentation requirements are not defined. A method can produce useful data and still create bottlenecks if quality review pathways are not ready.

This is where project execution matters.

Implementation should connect analytical development, quality, manufacturing, validation, regulatory, IT, data governance, vendors, and project leadership. If those groups move separately, the project may appear active while readiness gaps quietly build.

What Teams Should Pressure-Test Now

Companies exploring or preparing for NGS-based adventitious agent detection should pressure-test readiness early.

Teams should ask whether the method has a defined intended use, whether validation requirements are clear, whether sample handling is controlled, whether data interpretation rules are documented, and whether bioinformatics tools are governed appropriately.

They should also confirm how NGS results will connect to existing safety testing, release strategy, deviation processes, investigations, regulatory submissions, and inspection readiness.

Vendor readiness should not be overlooked. If a CRO, technology provider, or sequencing partner is involved, teams need clear expectations around documentation, data packages, turnaround times, change control, method transfer, and quality responsibilities.

The goal is not just to add a better test.

The goal is to make sure the testing strategy can support a controlled, compliant, and reliable manufacturing program.

The Persperity Perspective

NGS-based adventitious agent detection is a strong example of where life sciences execution is heading.

The industry is adopting better tools, stronger analytical technologies, and more advanced methods. But advanced methods only create value when teams can implement them with discipline.

Persperity supports complex projects in life sciences, pharmaceutical manufacturing, biotech, medical devices, CQV, C&V, project controls, validation, startup readiness, and regulated manufacturing.

For programs involving new testing approaches, biologics readiness, advanced therapy manufacturing, or quality system change, Persperity helps teams organize workstreams, align stakeholders, strengthen documentation, coordinate vendors, support validation planning, and keep execution moving.

NGS may help biologics manufacturers improve safety testing, but the real differentiator will be readiness.

Because in regulated manufacturing, the question is never just, “Can the technology work?”

The question is, “Can the organization execute it with control?”